Medicare's New Weight-Loss Drug Program: What You Need to Know

Medicare launched a temporary program on July 1, 2026, that covers three weight-loss GLP-1 drugs — Wegovy, Zepbound (injection version), and Foundayo (pill) — for a flat $50 monthly copay. This is a big deal. Until now, Medicare was legally barred from paying for weight-loss drugs at all. The Inflation Reduction Act changed that law, and this program is how the government is testing it out.

Here's what makes this different from regular Medicare prescription coverage: it operates as a separate lane outside the standard drug benefit. You don't have to meet a deductible or hit the usual cost-sharing tiers. You just pay $50 per month, full stop. For context, these drugs cost well over $1,000 per month without insurance. Under normal Medicare rules, you'd likely pay hundreds more out of pocket.

Who Qualifies and How the Program Works

To use this program, you need two things: a Medicare Part D prescription drug plan, and a doctor's prescription saying you're using the drug specifically for weight loss. That second part matters. If your doctor prescribes a GLP-1 for type 2 diabetes instead, you get covered through the regular Part D system. The Bridge program is only for obesity.

The flat $50 copay is intentional design. Medicare is keeping your costs visible and predictable while also making the drug affordable enough that people will actually use it. The agency is treating this like a real-world test: they want to see how many people take it, whether it works, and what the real-world costs turn out to be.

The program runs through December 31, 2027 — that's 18 months. That's deliberately short. It gives Medicare time to collect data before deciding whether to make this permanent or change it.

Insurance Plans Don't Have to Participate

Here's a wrinkle: drug insurance plans don't have to join this program. It's voluntary. Some plans will offer it; others won't. That means you'll need to check whether your specific Part D plan is in or out. If it is, great. If not, you're back to standard cost-sharing rules. This creates a patchwork across the country — your coverage depends on which plan you're in.

The Medicaid Picture Shows Why This Matters

State Medicaid programs — which cover low-income Americans — tell us something useful. A report from the Department of Health and Human Services in December 2024 found that Medicaid spent over $9 billion on diabetes and weight-loss drugs in 2023. That's five times what it spent in just four years earlier. Most of that spending was on diabetes drugs, because most states don't cover these drugs for weight loss yet. If they did, spending would climb sharply.

Medicare is starting smaller and more cautiously. The Bridge program is testing the waters.

What This Means for Drug Companies

Coverage by Medicare — even temporary coverage — matters enormously to drug makers. It opens a market of 67 million Medicare beneficiaries for the weight-loss indication specifically. Companies like Novo Nordisk (which makes Wegovy) and Eli Lilly (which makes Zepbound) have been building up manufacturing capacity in preparation for exactly this moment.

Foundayo's inclusion as a pill option (rather than a shot) may help some older patients stick with the treatment longer. And having three drugs available from the start gives plan sponsors and prescribers genuine choice.

The Bigger Picture

The 18-month window is short enough that Medicare keeps its options open. If too many people sign up and costs explode, or if the drugs don't deliver the outcomes the agency expected, it can shut the program down or redesign it by end-2027 without having locked in a permanent benefit. That flexibility is by design. Market participants — plan sponsors, manufacturers, pharmacy benefit managers — should understand that this program may not become permanent, and the agency may change the rules midway through.

What we're looking at is a pilot. The government is learning, in real time, what Medicare coverage for weight-loss drugs looks like in practice.